Claims Drawing Regulatory Attention FDA has indicated that compounded products generally should not be promoted using claims that: Suggest FDA approval Imply therapeutic equivalence Claim generic status without approval Guarantee clinical outcomes Misrepresent safety profiles Compare performance to approved products without evidence Marketing communications must be carefully reviewed to avoid misleading representations
You are unable to purchase this product
#Cardiology #LipidManagement #ESC2025 #EAS2025 #Statins #Inclisiran #PCSK9 #BempedoicAcid #MedicalUpdate To view or add a comment, sign in The Antiarrhythmic King: Mastering Amiodarone in Cardiac Arrest Amiodarone reigns as the first-line antiarrhythmic in the ACLS algorithm when defibrillation and epinephrine fail to restore a perfusing rhythm
Discontinuation was defined as having more than a 60-day gap in filling their GLP-1 prescriptions
Those following weight management programmes
Because the drug binds to the GLP-1 receptors in the body, Ozempic promotes the secretion of insulin, reduces glucagon production (which lowers blood sugar), and slows down stomach emptying, leading to a decreased appetite
